drugset / Trial / NCT01563536
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir) administered as two-day monotherapy followed by ABT-267 in combination therapy with other direct-acting antiviral agents (DAAs) ABT-450 with ritonavir (ABT-450/r) and ABT-333 (also known as dasabuvir) plus ribavirin (RBV) in patients with chronic Hepatitis C virus (HCV) infection without cirrhosis.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-04
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ombitasvir | Small molecule | 1.5 mg | — |
| Subject | ombitasvir | Small molecule | 25 mg | — |
| Background | Ribavirin | Small molecule | 1000 mg | — |
| Background | Ribavirin | Small molecule | 1200 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |
| Background | dasabuvir | Small molecule | 400 mg | — |
| Background | paritaprevir | Small molecule | 150 mg | — |